This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion's Promising Drugs Under Review, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
Amarin's Shares Down on Underperform Rating by Oppenheimer
by Zacks Equity Research
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.
Protalix Finalizes Accelerated Approval Pathway for PRX-102
by Zacks Equity Research
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Top Stock Reports for Chevron, HSBC & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), HSBC Holdings (HSBC) and Sanofi (SNY).
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
by Zacks Equity Research
GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
by Zacks Equity Research
Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength
by Zacks Equity Research
Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
by Zacks Equity Research
Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
by Zacks Equity Research
Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
Novavax Begins Phase III Study on Influenza Vaccine Candidate
by Zacks Equity Research
Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.
7 Value Price-to-Sales Stocks Poised to Fetch Strong Gains
by Zacks Equity Research
A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.
Abbott Forms Alliance With Omada Health for Diabetes Care
by Zacks Equity Research
Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.